The Cancer Letter

Inside information on cancer research and drug development

In Brief

Thomas Jefferson University joins TriNetX research network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THOMAS JEFFERSON UNIVERSITY joined the TriNetX network for clinical trial design and to support Jefferson’s clinical research programs.

Pharmaceutical researchers will be able to access Jefferson’s de-identified clinical data through TriNetX’s network of healthcare institutions to support clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages.

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

In The Headlines: Kimryn Rathmell on loss and caring for our community in uncertain times

In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.
White House

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology

Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.
By Claire Marie Porter and Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account